In particular, for breast cancer, ONCOMINE analysis revealed that collectively S100 mRNA expression was higher in tumoral than normal samples (55 analyses with up-regulation versus 27 analyses with down-regulation) and only S100A3 and S100A5 did not show differences between the analyzed dataset. This evidence concerns the gene S100A3 and breast carcinoma.